evaluated in all patients enrolled in the study in Japan. All variables were summarized using descriptive statistics. Data are presented as the mean (± standard deviation [SD]), unless otherwise stated. Height SDS and HV SDS were calculated according to published standards for Japanese children [3, 4] , and IGF-I SDS and IGF binding protein-3 (IGFBP-3) SDS were calculated according to published standards for healthy individuals [5, 6] . Statistical analyses were conducted using SAS software, Version 8.02 (SAS Institute, USA).
Results

Patient characteristics
In Japan, 1548 patients with short stature were enrolled in GeNeSIS: 1397 (90.2%) had GHD; 90 (5.8%) had TS; 57 (3.7%) had other causes of short stature; and the cause was unknown in 4 patients. The majority of patients were prepubertal at study entry: 92.3% of boys (704/763) were Tanner stage G1 and 88.5% of girls (478/540) were Tanner stage B1.
For the 1129 patients with GHD who were treatment-naïve at study entry, 62.6% were male and the mean chronological age was 8.75 (3.32) years (range 0.5, 17.1 years; Table 1 ). The age distribution at study entry tended to show two peaks (5, 11 years) for both the GHD and TS groups (Fig. 1) . The height parameters at study entry indicated that the GHD and TS groups were shorter and had a slower growth rate than the reference population ( Table 1) .
The cause of GHD was idiopathic in the majority of patients (914/981, 93.2%). Of the 67 (6.8%) patients with organic GHD, 34 (50.7%) had congenital GHD and 33 (49.3%) had acquired GHD (9 of whom also had germinoma). Complete GHD was present in 260/921 patients (28.2%) and partial GHD in 519/921 patients (56.4%). Of the patients with organic GHD, 52.2% (35/67) also had a deficiency in TSH, 28.4% (19/67) in FSH, 34.3% (23/67) in cortisol/ACTH, 23.9% (16/67) in antidiuretic hormone, 13.4% (9/67) in prolactin, and 4.5% (3/67) in LH.
Treatment dose and duration
The mean average dose of GH and mean treatment duration were 0.19 mg/kg/week and 3.03 years, respectively, in the GHD group and 0.33 mg/kg/week and 3.04 years, respectively, in the TS group ( Table 2) . The mean starting, cessation, and average doses of GH were similar between boys and girls in the GHD group,
Materials and Methods
Study information
GeNeSIS is an open-label, multinational, multicenter, observational study conducted in 30 countries, including Japan (ClinicalTrials.gov Identifier: NCT01088412). This interim report describes the results for Japanese patients enrolled from July 1999 to June 2008. The study was conducted in accordance with the Declaration of Helsinki, with approval from participating institutional ethics review boards. Written informed consent was required from the parents or legal guardians of the pediatric patients.
Study design
Patients diagnosed with GHD or TS (based on the criteria from the Study Group of HypothalamusPituitary Disorders, funded by the Japanese Ministry of Health, Labour and Welfare [1] ) were enrolled. Complete GHD was defined as a GH peak concentration of ≤ 5 ng/mL and partial GHD as a GH peak concentration of > 5 ng/mL to ≤ 10 ng/mL (before April 2005; after April 2005, the standard reference range in use at the time was used).
Patients with GHD were administered GH (Humatrope ® ) 0.175 mg/kg/week and patients with TS were administered GH 0.35 mg/kg/week [2] . Height was recorded at study entry and the 6-monthly study visits. Laboratory data and bone age were collected at each visit, if available.
Study objectives
The aim of the study was to assess the effectiveness and safety of long-term GH use in pediatric patients. Efficacy outcomes included height standard deviation score (SDS), height velocity (HV), HV SDS, and insulin-like growth factor-I (IGF-I) SDS. Safety outcomes included the frequency and nature of treatment-related adverse events (AEs), serious adverse events (SAEs), and AEs related to glucose intolerance. The relationship between GH treatment and AEs was assessed by the primary doctor.
Statistical analysis
Efficacy outcomes were evaluated in patients with GHD or TS who were evaluable for efficacy, treatment-naïve at study entry, received GH treatment, and had height SDS data available at study entry and the 1-, 2-, 3-, and 4-year time points. Safety outcomes were as were the mean total treatment duration and time to onset of puberty ( Table 2) .
Effects of GH on height parameters
In the GHD group, mean height SDS increased each year during the 4 years of treatment ( Fig. 2A) . However, the magnitude of change in height SDS declined with each successive year (Fig. 2B) . The effect of treatment varied with GHD severity, with initially greater mean changes in height SDS observed in patients with complete GHD than those with partial GHD (Fig. 3) . Effects on mean height SDS were also greater in the first year compared with subsequent years in the TS group (Fig. 4A, 4B ).
In the GHD group, the mean HV and mean HV SDS were 4.68 (1.43) cm/year and -1.30 (1.23) SD, respectively, before treatment, and these values increased to 8.24 (1.86) cm/year and 2.09 (1.57) SD, respectively, after 1 year of GH treatment (Fig. 2C, 2D) . A similar pattern was observed in the TS group. The mean HV and mean HV SDS were 4.14 (1.09) cm/year and -1.69 (0.71), respectively, before treatment, and these val- Table 1 Characteristics of patients with GHD and TS at study entry
CA ( Patients with GHD who were treatment-naïve at study entry only. related to glucose intolerance, of which 2 AEs were considered related to GH (diabetes mellitus, increased glycosylated hemoglobin); the relatedness was not known for 2 AEs (hyperglycemia, glucose present in the urine). Two patients had an oral glucose tolerance test. In the TS group, 1 patient experienced type 2 diabetes mellitus (not considered related to GH).
Discussion
In this large-scale study, GH treatment was effective in increasing height in Japanese children with GHD or TS, and had a favorable safety profile. The results reported here are broadly consistent with published studies [7] [8] [9] [10] [11] [12] [13] [14] .
The mean IGF-I SDS was higher in the TS group than the GHD group during this study, most likely because of the higher dosing of GH in the TS group. Although the TS group received nearly twice the dose of GH of the GHD group, the results were similar in the two groups, indicating that TS is resistant to GH compared with GHD. Elevated IGF-I levels have been observed in other studies of GH in TS [11, 15, 16] ; however, the potential adverse effects during the growth period are not fully known. As there is a proposed increased risk of cancer associated with elevated IGF-I levels [17, 18] , IGF-I levels should be monitored in patients with TS receiving GH treatment [19, 20] . In this study, 23.5% of patients in the TS group had an IGF-I SDS over 2.5 SD after 3 years of treatment.
The incidence of treatment-related AEs and SAEs ues increased to 8.15 (1.30) cm/year and 1.97 (1.27), respectively, after 1 year of treatment (Fig. 4C, 4D ). Mean HV and mean HV SDS subsequently decreased with each successive year in both groups (Figs. 2C,  2D, 4C, 4D ).
Effects of GH on IGF-I levels
The mean IGF-I SDS increased from study entry and was a little higher than (GHD group, Fig. 5A ) or higher than (TS group, Fig. 5B ) the mean for the reference population over the 4 years of treatment.
After 3 years of treatment, 69/379 patients (18.2%) in the GHD group and 11/34 patients (32.4%) in the TS group had an IGF-1 SDS over 2.0 SD; 49/379 (12.9%) and 8/34 (23.5%) patients had an IGF-1 SDS over 2.5 SD in the GHD and TS groups, respectively.
Safety
In the safety population (N = 1548), 45 patients (2.9%) in the GHD group reported 54 treatment-related AEs; the two most frequently reported were joint pain (18 cases, 12 patients) and hypothyroidism (6 cases, 6 patients). Twenty patients (1.3%) reported 30 SAEs, most frequently pneumonia (4) and craniopharyngioma (2); 4 SAEs were considered related to GH (craniopharyngioma, neurofibroma, scoliosis, diabetes mellitus). There were 2 treatment-related adverse events reported by 2 patients (0.1%) in the TS group: (proteinuria, scoliosis). One patient (0.1%) reported an SAE (tympanic membrane perforation, not considered related to GH).
In the GHD group, 7 patients experienced an AE A B
Fig. 5 Treatment effect of GH over 4 years on IGF-I SDS in the GHD (A) and TS (B) groups
The mean values are shown above the plots. GHD, growth hormone deficiency; IGF, insulin-like growth factor; Q1, 25 th percentile; Q3, 75 th percentile; SD, standard deviation; SDS, standard deviation score; TS, Turner syndrome was relatively low in both the GHD and TS groups.
The most frequently reported treatment-related AE was joint pain, a known side effect of GH related to its ability to stimulate growth [21] . There were two neoplasms considered related to GH. Extensive monitoring of the safety of GH therapy has revealed no increase in the incidence of de novo cancer or leukemia in patients without risk factors and no evidence that GH treatment increases the risk of tumor recurrence in patients successfully treated for their primary lesion [19, 20, 22, 23] . However, patients at high risk of developing a neoplasm should be monitored. Two patients reported AEs related to glucose intolerance that were considered related to GH. Growth hormone may decrease insulin sensitivity, particularly at higher doses in susceptible patients, leading to unmasking of previously undiagnosed impaired glucose tolerance and overt diabetes mellitus [19, 20, 24, 25] . The observational study design of GeNeSIS allowed evaluation of GH in real-world clinical practice. The large number of patients enrolled allowed detection of infrequently occurring AEs; however, the number of patients with TS was small, in particular, the number with 4-year data. In addition, GHD is a rare childhood disorder, making it difficult to conduct a largescale study. However, as there are very strict criteria for GHD that must be fulfilled to receive GH treatment in Japan [26] , the diagnosis of GHD in this study is expected to be accurate. The best measure of the overall effectiveness of GH in treating short stature is adult height; however, sufficient adult height data are not currently available in this study.
In conclusion, GH treatment in patients with GHD or TS resulted in increased growth, although the improvements tended to decline with time. Insulin growth factor-I levels were normalized in the GHD group and elevated in the TS group. Future investigations will report long-term effectiveness data, such as adult height, and further long-term safety data, including the incidence of neoplasms and glucose intolerance.
